Lundbeck backs Trintellix with new data
New clinical data from a trial involving Lundbeck's Trintellix in patients with depression and anxiety will put wind in the drug's sails.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
A particular group of patients have proven to benefit from being treated with Lundbeck's Trintellix/Brintellix – a group which has otherwise had difficulty finding treatment, according to a Lundbeck press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer buys Amplyx Pharmaceuticals from Lundbeckfonden
For subscribers
Lundbeck eyes major breakthrough for brain diseases
For subscribers
